Myeloma Paper of the Day, September 12th, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: ISB 2001 trispecific T cell engager co-targeting BCMA and CD38 shows strong tumor cytotoxicity and overcomes immune escape mechanisms of myeloma cells w/ a reduced T cell activation profile in the absence of tumor.”

Source: Robert Orlowski/X

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

Authors: Laura Carretero-Iglesia, Olivia J Hall, Jérémy Berret, Daniela Pais,Carole Estoppey, Myriam Chimen, Thierry Monney, Jeremy Loyau, Cyrille Dreyfus, Julie Macoin, Cynthia Perez, Vinu Menon, Isabelle Gruber, Amélie Laurendon, Lydia N Caro, Girish S Gudi, Tomomi Matsuura, Piet H van der Graaf, Stanislas Blein, M Lamine Mbow, Rebecca Croasdale-Wood, Ankita Srivastava, Michael R Dyson, Thomas Matthes, Zeynep Kaya, Claire M Edwards, James R Edwards, Sophie Maiga, Catherine Pellat-Deceunynck, Cyrille Touzeau, Philippe Moreau, Cyril Konto, Adam Drake, Eugene A Zhukovsky, Mario Perro, Maria Pihlgren

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.